(Q42822334)

8 November 2017

Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. (English)

1 reference

8 November 2017

whole genome sequencing

1 reference

4

Victor E Velculescu

1 reference

8 November 2017

Luis A Diaz

1

1 reference

8 November 2017

Mark Sausen

series ordinal

2

1 reference

8 November 2017

George A Fisher

series ordinal

3

1 reference

8 November 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

8 November 2017

1 reference

8 November 2017

4

1 reference

8 November 2017

10

1 reference

8 November 2017

1856-1857

1 reference

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

8 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3858570

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3858570

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3858570

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3858570

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3858570

Drug development of MET inhibitors: targeting oncogene addiction and expedience

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3858570

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3858570

27 May 2018

Identifiers

DOI

10.18632/ONCOTARGET.1486

0 references

1 reference

8 November 2017

PubMed publication ID

24196513

1 reference